April 08, 2025 -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS) and The Gut Doctor PodcastLLC to promote esophageal cancer prevention, education and advocacy. “As eso

April 07, 2025 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million. “We have reached another key milestone with the closing on the sale of our PRV, which we received following the successful approval of MIPLYFFATM (arimoclomol) from the U.S. Food and

Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of next-generation HDAC6 inhibitors (HDAC6i) also to be advanced in significant cardio-metabolic and neurodegenerative diseases 24 March 2025 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology co

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy March 17, 2025 -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer man

March 18, 2025 -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues of ILUVIEN and YUTIQ for a one-time payment of $17.25 million. Under the terms of the agreement, upon making the buyout payment, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. ANI funded the buyout with cash on hand. Nikhil Lalwani, Pres

March 17, 2025 -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO’s proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera’s proprietary

March 13, 2025 -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia’s cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual trea

March 13, 2025 -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets. This collaboration aims to advance the discovery and development of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters and other integral membrane proteins in therapeutic areas such as mental

美通社消息，全球领先的专注于提供抗体偶联药物（ADC）等生物偶联药物端到端CRDMO服务的药明合联（WuXi XDC），宣布与韩国生物技术公司AbTis签署战略合作意向书（MOU）。本次合作将深度融合AbTis专有的定点偶联技术平台AbClick®与药明合联一体化研发服务和一站式研发与生产平台，旨在为客户打造集先进定点偶联技术与强大专业ADC研发能力于一体的创新解决方案，加速新型ADC药物的开发进程，赋能全球客户，并创造更多发展机遇。 根据协议，药明合联将纳入AbTis的先进定点偶联技术平台AbClick®。该技术平台通过亲和肽辅助，实现精准高效的抗体-药物偶联。药明合联将依托其广泛的全球客户网络，全力推动AbTis技术的广泛应用，助力双方在生物偶联药领域的深度合作与共赢。此次合作充分彰显了两家公司在推动技术创新与赋能生物制药行业的共同愿景。通过整合双方的技术与强化服务能力，为客户缩短开发周期、优化研发流程，并加速创新型ADC药物的研发推进。 内容来源于网络，如有侵权，请联系删除。

3月6日，中国生物制药发布公告，集团与南京清普生物就其研发的国家2类新药QP001在中国大陆地区达成独家合作协议。预计该产品将于近期获国家药监局批准上市。 QP001是目前唯一一款注册分类为国家2类新药的美洛昔康注射液，是一种长效、强效的针对术后疼痛的新型非甾体抗炎药(NSAID)，已在中国和美国申报上市。 相较于传统非选择性NSAIDs，QP001是一种选择性环氧合酶-2(COX-2)抑制剂，通过抑制炎症和疼痛部位上调的COX-2活性，减少或阻断患处前列腺素(PGs)的合成，从而起到抗炎和镇痛的作用，且对广泛表达于人体各种组织并对维持正常生理功能起重要作用的环氧合酶-1(COX-1)影响较小。 QP001单次注射即可实现24小时的持续强效镇痛，是中国首款一日一次的长效镇痛NSAID注射液。两项III期临床研究显示，QP001在药效末期（即18-24小时）仍可保持显著镇痛效果。目前临床常用于术后镇痛的注射药物需要一日多次注射，或通过留置导管持续给药。 QP001可以有效解决给药间隙疼痛的问题，尤其是术后住院过程的夜间疼痛，从而显著提升患者的依从性、节约医护资源。同时，QP001